Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
February 09 2023 - 7:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that it will report its fourth-quarter 2022 financial
results on Thursday, February 23, 2023. Vericel’s management will
host a conference call and webcast at 8:30 a.m. (ET) to discuss the
results and certain business highlights.
The live webcast can be accessed on the Investor
Relations section of the Vericel website at
http://investors.vcel.com/events-presentations. Please visit the
site at least 15 minutes prior to the scheduled start time in order
to register and download the required audio software, if necessary.
Presentation slides for the conference call will be available on
the webcast and on the Investor Relations section of the Vericel
website.
To participate by telephone, please register
here to receive dial-in details and your personal passcode. A
replay of the webcast will be available on the Vericel website
until February 23, 2024.
About Vericel Corporation
Vericel is a leader in advanced therapies for
sports medicine and severe burn care. The Company manufactures and
markets two cell therapy products and one specialty biologic
product in the United States. MACI® (autologous cultured
chondrocytes on porcine collagen membrane) is an autologous
cellularized scaffold product indicated for the repair of
symptomatic, single or multiple full-thickness cartilage defects of
the knee with or without bone involvement in adults. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. Vericel
also holds an exclusive license for North American rights to
NexoBrid® (anacaulase-bcdb), a biological orphan product containing
proteolytic enzymes, which is indicated for the removal of eschar
in adults with deep partial-thickness and/or full-thickness burns.
For more information, please visit www.vcel.com.
Epicel® and MACI® are registered trademarks of
Vericel Corporation. NexoBrid® is a registered trademark of
MediWound Ltd. and is used under license to Vericel Corporation. ©
2023 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burnsir@vcel.com+1 (734) 418-4411
Media Contact:
Julie Downsmedia@vcel.com
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024